Description
ADCC-enhanced Anrukinzumab is a non-fucosylated anti-IL13 therapeutic biobetter antibody.
Indication
Cancers, Asthma, Idiopathic Pulmonary Fibrosis, Eosinophilic Esophagitis, Keloids, Crohn's Disease
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced IL13 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Background
This gene encodes an immunoregulatory cytokine produced primarily by activated Th2 cells. This cytokine is involved in several stages of B-cell maturation and differentiation. It up-regulates CD23 and MHC class II expression, and promotes IgE isotype switching of B cells. This cytokine down-regulates macrophage activity, thereby inhibits the production of pro-inflammatory cytokines and chemokines. This cytokine is found to be critical to the pathogenesis of allergen-induced asthma but operates through mechanisms independent of IgE and eosinophils. This gene, IL3, IL5, IL4, and CSF2 form a cytokine gene cluster on chromosome 5q, with this gene particularly close to IL4. [provided by RefSeq, Jul 2008]
Alternative Names
Interleukin 13; IL-13
Cellular Localization
Extracellular region or secreted
Involvement in Disease
Diseases associated with IL13 include Asthma and Allergic Rhinitis.
Related Pathways
Its related pathways are Immune response Fc epsilon RI pathway and PEDF Induced Signaling.
Function
Cytokines. Inhibit the production of inflammatory cytokines. Co-regulates interferon-gamma synthesis with IL2. May play a key role in regulating inflammation and immune response. Positive regulation of IL31RA expression in macrophages (through similarity).
Post-translational modifications
Glycosylation at Asn52, Asn63, Asn71, and Asn86
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Clone
Anrukinzumab
Description
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant Humanized (from mouse) antibody to Human IL13. Anrukinzumab (IMA-638) is a humanized monoclonal antibody designed for the treatment of asthma.
Indication
Cancers, Asthma, Idiopathic Pulmonary Fibrosis, Eosinophilic Esophagitis, Keloids, Crohn's Disease
